Axsome Therapeutics Company Leadership

Axsome Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.1979) % which means that it has lost $0.1979 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.755) %, meaning that it created substantial loss on money invested by shareholders. Axsome Therapeutics' management efficiency ratios could be used to measure how well Axsome Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 31st of January 2026, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.78. At this time, Axsome Therapeutics' Other Assets are very stable compared to the past year. As of the 31st of January 2026, Intangibles To Total Assets is likely to grow to 0.15, while Return On Tangible Assets are likely to drop (0.53). As of the 31st of January 2026, Common Stock Shares Outstanding is likely to drop to about 31.5 M. In addition to that, Net Loss is likely to grow to about (160 M)Axsome Therapeutics holds a total of 50.41 Million outstanding shares. The majority of Axsome Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Axsome Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Axsome Therapeutics. Please pay attention to any change in the institutional holdings of Axsome Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Axsome Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Axsome Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Axsome Therapeutics Workforce Comparison

Axsome Therapeutics Profit Margins

The company has Profit Margin (PM) of (0.41) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.19) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.19.

Axsome Therapeutics Insider Trading History

Axsome Therapeutics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Axsome Therapeutics often depends on how effective the management is. Axsome Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Axsome management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Axsome management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.

Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.